UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024
Rhea-AI Summary
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on cancer treatment, has announced it will provide a corporate update for Q2 2024 on Tuesday, August 13, 2024. The company will host a conference call and webcast at 8:30 am Eastern Time to discuss financial results and provide an overview. Investors can join the call toll-free at 1-800-717-1738, and a webcast link is available. A replay of the call will be accessible on the Events section of Cellectar's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – CLRB
On the day this news was published, CLRB declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will provide a corporate update for the three months ended June 30, 2024, on Tuesday, August 13, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time. Details for the call are as follows:
Conference Call & Webcast Details:
Date: Tuesday, August 13, 2024
Time: 8:30 am Eastern Time
Toll Free: 1-800-717-1738
Webcast: Click HERE
A replay of the call will be available on Events section of the company’s investor relations website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
For more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
Contacts
MEDIA:
Claire LaCagnina
Bliss Bio Health
315-765-1462
clacagnina@blissbiohealth.com
INVESTORS:
Chad Kolean
Chief Financial Officer
investors@cellectar.com
